Tomorrow, on the 30th of May, our Tissue & Scaffold Characterization Unit 13 organises the Conference “Understanding cardiovascular disease by means of Computation Fluid Dynamics” by Prof. Shirley Jansen.
The event will take place at 12:30 in the I3A Seminar Room, Block 5, 2nd floor of the R&D Building in Campus Rio Ebro of Universidad de Zaragoza.
Prof. Jansen is passionate about the importance of working alongside engineers to understand the mechanics behind many vascular pathologies such as aortic aneurysm, dissection, and peripheral arterial disease, and why close collaboration via a shared language of haemodynamics can shed light on risk prediction, inform patient specific intervention and optimise outcomes. Understanding of device failure mechanisms in pressurised circuits will inform innovation of next generation devices but the way in which we handle the use of assumptions in CFD in particular, is crucial to the engagement between vascular surgeons and bioengineers.
About the speaker
Prof. Shirley Jansen
Professor Shirley Jansen is Joint Program Head of Cardiovascular Science and Diabetes as well as Director of the Heart and Vascular Research Institute at the Perkins and has led her unit to great success in first in man, pharmacological and device related trials in vascular disease. She is also Head of Dept of Vascular and Endovascular Surgery at Sir Charles Gairdner Hospital, a busy quaternary unit overseeing 900 in-patients per year. She was awarded PhD in 1999 and The Sustained Overall Clinical Excellence Award from Sir Charles Gairdner Hospital in 2016.
She has run over 30 government and industry sponsored clinical trials, the majority as PI/site PI. She supervises six PhDs and four Masters and numerous other projects covering a wide range of vascular pathologies. Her main research interests since PhD are in the clinical management of carotid, peripheral vascular disease, diabetic foot disease and venous leg ulcers, as well as the interface with bioengineering and innovation.
Jansen has wide experience in all aspects of vascular, endovascular surgery, perioperative care and prevention and health outcomes. She has published over 60 research papers and five chapters, and given over 50 presentations at national and international meetings. She has received eight travelling fellowships in her career. She is also an inventor, and convenor of two national/international vascular surgical training workshops. Shirley is actively engaged in cross-disciplinary collaborations locally and internationally in the areas of imaging, treatment modalities and outcomes for vascular diseases.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions, place your request here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
